• Users Online: 311
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 16  |  Issue : 3  |  Page : 282-287

Deceased donor renal transplant outcome in a south Indian tertiary care hospital with zonal allocation model - An observational study


1 Department of Nephrology, Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India
2 Department of Urology, Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India
3 Department of Vascular Surgery, Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India
4 Department of Urology, GKNM Hospital, Coimbatore, Tamil Nadu, India
5 Department of Surgery, Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India
6 Department of Community Medicine, KMCH Medical College Hospital, Coimbatore, Tamil Nadu, India

Correspondence Address:
Dr. Kandasamy Sadayandi
Department of Nephrology, Kovai Medical Centre and Hospital, Avinashi Road, Coimbatore - 641 014, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijot.ijot_112_21

Rights and Permissions

Background: With the rising incidence of diabetes and hypertension, the prevalence of end-stage renal disease has increased greatly so as the need for renal replacement therapy. Availability of suitable living-related donors is a major problem which increases the demand for deceased donor renal transplantation (DDRT), making it a lifeline for the patients on dialysis without any living donors. Methodology: This is a retrospective analysis of 118 DDRT done between 2012 and 2020, in a private quaternary care hospital in a south Indian state. All patients received basiliximab induction, with maintenance immunosuppression using steroids, mycophenolate mofetil (MMF) or mycophenolate sodium, and tacrolimus. Results: In our study, we report unadjusted graft survival of 93.2% and 81.3%, patient survival of 94.9% and 83.1% at the end of 1 and 5 years, respectively. The recipients with age < 60 years had 5 years graft survival of 87%. The study group consisted of 15.25% of the patients with panel reactive antibody (PRA) positive and 10.16% of them with donor-specific antibody (DSA) during renal transplantation, and there was only one allograft loss in this subset of the patients. Conclusion: This study confirms that human leukocyte antigen matching is not very important with the current immunosuppressive protocol using tacrolimus and MMF. Early initiations of tacrolimus do not increase the incidence of delayed graft function. We report 91.6% graft survival in the DSA-positive group, with basiliximab induction and desensitization protocol.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed274    
    Printed18    
    Emailed0    
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal